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Spinal cord stimulation (SCS), as a neuromodulation therapy, has rapidly 
evolved over the past few decades to become the treatment of choice for many 
chronic pain syndromes. However, many equipment-related limitations such as the 
bulk of the equipment, an implantable pulse generator (IPG), the limited therapeu-
tic stimulation frequency utilized, and the potential adverse events have restricted 
SCS applications. Recently, advanced nanotechnology and minimally invasive 
surgical techniques have shown promising options to expand the indications due to 
reduced surgical trauma/hospital time/costs. We describe the basis for nanotech-
nology neuromodulation and the preliminary experience with wireless SCS in the 
treatment of chronic pain conditions. The equipment utilizes a miniature stimulator 
with microelectronics, percutaneously placed at the appropriate stimulation target, 
with wireless control to provide the desired stimulation, and then moderated by the 
clinician and the patient. The wireless device reduces the bulk of the SCS equipment 
to a single electrode (with embedded sensors), using the new improved neural-
electric interface. This wireless neuromodulation (WNM) has been clinically used 
in several chronic pain conditions, including failed back surgery syndrome, facial 
pain, chronic regional pain syndrome, and postherpetic neuralgia, with encourag-
ing outcome, without the complications of a traditional SCS resulting from the IPG 
or its accessories.
Keywords: neuromodulation, wireless, nanotechnology, chronic pain,  
spinal cord stimulation
1. Introduction
Therapeutic modulation of excitable neural tissues in the body by electrical 
stimulation has become an important intervention to manage chronic disabling 
conditions like pain, involuntary movements, extrapyramidal syndromes, chronic 
peripheral vascular disease, and cardiac arrhythmias [1–9]. Devices are being 
implanted to deliver stimulatory signals to the target tissue, record vital signs or 
action potentials, perform electric cardiac pacing, and control drug release, as well 
as interface with auditory systems for assisted hearing or even image formation 
for visual prosthesis. All these systems utilize a subcutaneous battery-operated 
implanted pulse generator (IPG) to provide power.
Spinal cord stimulation (SCS) has been utilized for over five decades to provide 
therapeutically effective pain relief from chronic conditions like failed back surgery 
syndrome (FBSS), regional pain syndromes, and neuralgias, reducing the need for 
opioids. Several measurable outcomes like pain scores, disability scores, and quality 
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of life scales have shown consistent improvement with SCS in patients with back 
pain and leg pain [1–3].
Outcomes following SCS therapy have demonstrated superior results compared 
to conservative medical treatment for patients with FBSS in several studies [2, 4],  
and SCS was also shown to be more cost-effective over the long term due to a 
decrease in follow-up visits, diagnostic tests, and overall consumption of healthcare 
facilities [4, 5]. Historically, on the other hand, SCS has not been devoid of compli-
cations and limitations in its conventional form utilizing an IPG, since the device 
options have had a long history of severe adverse events primarily related to the 
IPG [6, 7]. A large percentage of patients, reportedly as high as 50%, have failed the 
trial period utilizing conventional SCS devices [6–8], while additional failures came 
from equipment complications caused by the migration/fracture of the electrodes as 
well as IPG failures and complications in recharging or reimplantation. Postsurgical 
complications like infection, hemorrhage, and painful operative wounds were 
frequently seen associated with IPG and its extension wires. Additionally, SCS in 
its conventional form is incapable of reaching some anatomical locations to provide 
targeted therapeutic localized pain relief [6, 8–12].
Several modifications have been introduced to the SCS equipment over the past 
few years, which have reduced adverse events while promoting the efficacy of the 
modality, thereby increasing the number of clinical indications [13]. Percutaneous 
techniques, smaller compact batteries, rechargeable batteries, increased life of the 
IPG, and improved anchoring methods are some of these modifications currently in 
use. Part of the refinement also comes from the advancements in the technology of 
nanomaterials and wireless power transfer techniques.
2. Nanoelectrodes and wireless technology for neuromodulation
An advancement in this field is the new miniature pulse generator (mini PG) 
with wireless access (WPG) utilizing a dipole antenna for electric field coupling. 
This is accomplished with “microwaves”, which are very short wavelength pulsed 
electromagnetic waves at gigahertz (GHz) frequencies. This device (Stimwave 
Technologies, Florida, USA), instead of using lower frequencies of 100 – 500 kHz 
of the inductive range operational in most of the present-day implanted medical 
devices, is powered by a radiative electric field coupling through tissues at micro-
wave frequencies that enable smaller-sized implants to be placed at a significant 
tissue depth through a percutaneous technique. It also affords minimal power loss, 
since the higher frequency allows a much better energy transfer to a smaller implant 
[14]. The principle behind the frequency changes in relation to the wavelength 
was elaborated earlier by Feynman: “If you build a corresponding circuit on a 
small scale, its natural frequency goes up, since the wave length goes down as the 
scale; but the skin depth only decreases with the square root of the scale ratio, and 
so resistive problems are of increasing difficulty. Possibly we can beat resistance 
through the use of superconductivity if the frequency is not too high, or by other 
tricks [15].”
Figure 1. 
MRI compatible electrode with nanostimulator and microcircuit to contact wireless pulse generator. This is the 
only implantable component required for WSCS.
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The micro-implant WPG is capable of delivering clinically appropriate stimula-
tion with dimensions of 800–1350 μm diameter, a significantly miniature size 
compared to the conventional SCS-IPG. This is equal to the size of a standard lead 
body that also incorporates the nanoelectronics within the device itself. It also can 
be integrated with a variety of lead types carrying four or eight contacts, either in 
a percutaneous or a paddle-type electrode, and the receiver wire has circuits in the 
stimulator device internally with wireless access (Figure 1).
3. The implantable wireless lead or the implantable neural  
stimulator (INS)
The INS has an enclosure housing the stimulating electrode array, designed to 
apply electrical pulses to the target tissue and antenna-1 and configured to receive 
electric energy input from an external antenna-2 through electrical radiative 
coupling. The antenna-2, physically separated from the INS lead, is connected to the 
antenna-1 by electric circuits configured to generate electrical pulses for stimulat-
ing the neural tissue (Figure 1).
4.  The nanoelectronic substrate of the miniature wireless  
pulse generator
The INS is without any power source and stays in contact with the excitable neu-
ral tissue with passive components capable of receiving an external input signal at a 
frequency between 300 MHz and 8 GHz. A controller module, positioned in prox-
imity to the patient body, to generate the input signals, sends them to the antenna-2; 
the latter transmits the input signal to the first dipole antenna placed within the INS 
through electrical radiative coupling, and antenna-1 extracts the stimulus feedback 
signal from signals received by the antenna-2 to adjust the parameters of the input 
signals based on the stimulus feedback.
The electrical pulses from the activated stimulating electrode, however, result in 
zero net charge within the patient’s body. The electrodes can be selectively marked 
as a stimulating return electrode or an inactive one. It can have one capacitor in 
series with one or more electrodes.
At present, several therapeutic intra-body electrical stimulation techniques 
are available to manage neuropathic pain. However, they utilize a bulky, heavy, 
subcutaneous IPG connected to the implantable wired leads and have many failures 
or adverse events like mechanical dislodgement, impingement of the lead extension 
cables, and infection, along with IPG-related discomfort, pain, and irritation. The 
lead configuration includes cylindrical percutaneous or paddle leads. Cylinders are 
usually 1.3 mm in diameter and contain several circular electrodes, which are used 
for trial testing, later followed by permanent placement by minimally invasive, 
percutaneous approach. Paddles contain electrodes with a wider surface area direc-
tionally targeted for control over neural excitation and require invasive surgical 
procedures like laminectomy or laminotomy.
INS is designed to be placed in the patient through an introducer or a needle with 
electrodes (Figure 2) that include a semicylindrical array of electrodes/contacts 
made up of platinum, or platinum-iridium, or gallium-nitride, or titanium-nitride, 
or iridium-oxide or similar combinations. The contacts can be 2–16 in number 
having a length of 1 to 6 mm and 0.4 to 3  mm in width. They are spaced 1 to 
6 mm apart with a combined surface area of 0.8 to 60 mm2. The lead can also be a 
paddle type, deliverable through a 14-gauge needle. The enclosure has an external 
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biocompatible coating of polymethyl methacrylate (PMMA), polydimethylsiloxane 
(PDMS), perylene, polyurethane, polytetrafluoroethylene (PTFE), polycarbonate, 
or a silicone elastomer.
The antenna-1 within the INS enclosure has 2 to 8 contacts, configured to couple 
with each other as well as the circuit, and these contacts are located proximally 
relative to the electrode inside the enclosure. These contacts are 1 to 6 mm in length, 
1 to 2.5 mm in width, and spaced 30 to 80 mm apart. One antenna is constructed as 
a conductive trace contained on the circuits and can be fabricated as a conductive 
wire connected to the circuits, which are flexible with a bend radius of 0.5 mm and 
located proximal in the enclosure with a waveform conditioning circuit.
5. Remote control of power or polarity selection for a neural stimulator
The dipole antenna receives input signals containing polarity assignment 
information and electrical energy, the former designating the polarities for the 
electrode contacts. The circuits are configured to control an electrode interface 
so that these electrode contacts have polarities designed by the polarity assign-
ment information to create electrical pulses from the electrical energy contained 
in the input signal. These electrical pulses reach the contacts according to the 
polarities assigned.
6.  The remote radiofrequency power system with a low-profile 
transmitting antenna
The antenna for this wireless system includes a metal signal layer with radiating 
surface, a feed port, a wave guide surrounding the antenna, and a configuration 
to guide electromagnetic (EM) energy transmitted from the radiating surface in a 
direction away from the antenna. It also has a controller module connected to the 
feed port to drive the antenna to transmit EM energy from the radiating surface, 
while the antenna, wave guide, and controller module are configured to match a 
reception characteristic of an implantable device, so that the latter can produce 
electrical pulses of sufficient amplitude to stimulate the target neural tissue utiliz-
ing the EM energy received from the antenna-2, located up to 10 cm away.
Adverse events related to the IPG, due to excessive absorption of EM energy, 
include burning of tissue, creation of undesirable blood clots, and skin irritation 
Figure 2. 
Minimally invasive approach to place the wireless implantable neural stimulator in the spinal epidural space.
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because of adhesions between the implant and tissues. A wireless device, on the 
other hand, has the antenna located outside the body with a controller module con-
necting the implantable device with the antenna (Figures 3 and 4).
The antenna has a dielectric lens filling the wave guide, protruding outward 
from an opening of the wave guide to narrow the transmitted EM energy and 
direct it away from the transmitting surface. It also has a return loss cutoff fre-
quency associated with the wave guide; the dielectric lens lowers the return loss 
of cutoff frequency. The antenna operates within 500 MHz to 4 GHz frequency 
band.
7. Wireless energy supply
The INS receives energy by a wireless method, which includes radiating 
EM energy from the surface on an antenna located up to 10 cm away, inside 
the patient, so that the implanted device creates appropriate electrical pulses 
to stimulate the target neural tissue, using the received EM energy, even during 
sleep. The radiating surface of the antenna can be placed 1 to 6 feet away from 
the INS and can be adjusted to increase the EM energy provided to the latter 
(Figure 3). The interface is facilitated by a link between the programmable 
module and the controller module so that the stimulation pulses created at 
the implantable device are transmitted as data-encoded parameters from the 
programming module to the controller module, thus effectively stimulating the 
neural tissue.
A dipole antenna receiver intercepts the high-frequency microwave EM energy 
coming from outside the body to produce an oscillating electric field. Frequencies in 
Figure 3. 
Remote access by wireless antenna (experimental setting).
Figure 4. 
Neurostimulator receiver. The contacts on the electrodes are managed by independently integrated, circuits that 
are application specific. The circuitry system within the device produces charge-balanced waveforms.
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the range of GHz were found to be more energy efficient [16]. Typically, the antenna 
within the device lumen can be anywhere from 2 to 8cm long and can be modified 
depending upon the indications and the depth at which the device is implanted, since 
the EM field energy is dissipated across the tissue layers of the skin, fat, muscle, blood 
vessels, and bone. The deeper the placement, the longer the antenna should be to 
receive adequate power. Each contact on the electrodes is provided with independent 
power, a part of an “application-specific” integrated circuit; the embedded circuitry 
within the device enables production of charge-balanced waveforms. This is managed 
by internalized addressing systems within the device (Figure 4). It is important to note 
that microwave fields are safe, since these high frequencies fail to activate cell mem-
branes and thus nervous tissue damage is unlikely.
8. Wireless pulse generator (WPG)
The WPG employs standard cellular phone technology, with an average pulse 
output power of up to 1 W, depending upon the stimulation parameters and accord-
ing to the requirements of the target tissue. A radiofrequency (RF) transmitter 
placed inside the WPG encodes stimulus waveforms into the signal according to 
the program settings. A microprocessor inside this transmitter controls the data 
communications and settings (Figures 3 and 4). Clinicians as well as patients com-
municate with the WPG via a controller that uses Bluetooth technology (Figure 5) 
and also can be accessed by a software application (app) on a mobile phone [14].
9. Discussion
The traditional SCS (TSCS) system has electrodes in a catheter enclosure 
attached to a long extension cable(s) that connects the electrodes to an IPG that 
is placed inside the patient’s body, inheriting the complications due to failure or 
malfunction of any of these components. Efforts have been ongoing to reduce 
the bulk of the implanted material and yet improve the efficiency of the system. 
Reduction in size has a challenge from the battery life expectancy with the conven-
tional energy settings. Thus, TSCS equipment requires implantation of electrodes, 
extension cables, and the battery inside the body, requiring multiple incisions along 
with long segment tunnels under the skin, producing considerable tissue trauma 
with pain and hemorrhage.
Figure 5. 
External wireless pulse generator.
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The wireless SCS system with nanotechnology has been clinically used for SCS, 
dorsal root ganglia (DRG) stimulation, and peripheral nerve stimulation (PNS) 
throughout Europe and the USA for several years, and multiple trials have shown 
encouraging results. The capabilities of this system enabled its utility to be tested in a 
variety of chronic pain syndromes. Poon et al. [16, 17] demonstrated that in a biologi-
cal media, the operating frequency for wireless-powered devices was in GHz range 
as opposed to the MHz, which could have potential advantages. At this frequency 
range, the size reduction of the receiver has been demonstrated in the subsequent 
studies by Tyler Perryman et al., while the tissue depth relationship to the energy 
transmission were further elaborated [17, 18]. Tyler Perryman et al. conducted stud-
ies in animals and verified the tissue depths at which the wireless stimulation could 
achieve effective current density [18]. The dipole antenna of the wireless system 
(at 915 MHz) could energize the stimulators implanted at a depth of 12 cm in porcine 
models, especially efficient with a 4.3 cm antenna. Successful stimulation has been 
observed to provide significant pain relief in patients with back and leg pain with 
FBSS [19, 20], post herpetic neuralgia [21], refractory craniofacial pain [22], occipi-
tal neuralgia [23], and CRPS [24]. Patients undergo implantation of the INS with 
integrated microcircuits enabling coupling with a pulse generator, while the wireless 
pulse generator circuit excludes surgical implantation of the IPG, thus eliminating 
complications related to multiple surgical incisions and interventions for failed IPG 
or its extension cables. Consequently, there is reduced operating time, minimal con-
sumables, and increased comfort to the patient. In the long run, this should decrease 
the costs of SCS and reduce overall healthcare budget in neuromodulation.
10.  Financial implications and economic benefits with the wireless 
neuromodulation technology
Every innovation carries financial burden, and there are economic repercussions 
as the inventions arrive into the clinical practice. For easy understanding, tradi-
tional SCS has a structure as follows:
1. Electrodes + connection cables + implantable pulse generator inside the patient 
body
2. External controller (for the patient as well as the clinician)
Conversely, wireless neuromodulation with nanotechnology utilizes only 
implantable stimulating electrodes and an implantable receiver placed in a micro-
incision pocket. Because of the reduced bulk of the implants, wireless technology 
has much more to offer other than the costs alone. It reduces surgical trauma, 
operating time, con-sumables, anesthesia, complications secondary to multiple 
incisions/tissue trauma, and hospital visits.
11. Costs involved with nanotechnology wireless SCS
Compared to the wireless neuromodulation, TSCS was reported to be more expen-
sive (Table 1). There have been limited reports on the costs and long-term maintenance 
The initial implantation of the wireless stimulator 18,000 Euros
IPG costs: Zero (0)
Annual maintenance of the neuromodulation cost 1500 Euros/3
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of TSCS in the literature. Detailed report on follow-up costs, complications, and 
replacement charges for reimplantation has not been forthcoming. However, the natural 
course of TSCS with its multiple implant components leading to their inherent com-
plications could be expected as reported in a few of the studies (Tables 1–3). Wireless 
neuromodulation is evolving, and only limited experience has been reported so far. 
However, large-scale multicenter studies have been initiated to improve our understand-
ing about the efficacy and acceptable long-term results in the form of improved quality 
of life, reduced complications, reduction in healthcare costs, and better cosmetic results.
12. Conclusions
Nanoelectronics have contributed to the development of miniature implants for 
therapeutic purposes, and wireless technology coupled with mini WPG appears 
Procedure TSCS USD* TSCS CAD* TSCS 
UKS*
Stimwave WSCS
Implantation 32,882 21,595 15,081 €18,000
Complication cost 9649 5191 576 NA
Revision cost 5450 5339 (lead) €2500
IPG cost 13,150 10,591 7243 0
Maintenance 5071 (4 years) 3539 (4 years) NA 1500 (3 years)
HF SCS therapy was similar to TSCS in its costs and complications. USD*,  US dollar; CAD*, Canadian dollar; 
UKS*, United Kingdom Sterling Pound.
Table 2. 
Reported costs of traditional SCS (TSCS) and the wireless SCS (WSCS).
Author Journal Year No. of 
patients
Cost
1. Manca et al. [25] European J Pain 2008 52 CAD 19,486, Euro 12,653
2. Kumar et al. [10] J Neurosurg Spine 2006 160 CAD 23,205
3. Kumar and Bishop [26] J Neurosurg Spine 2009 197 CAD 21,595, USD 32,882
4. Hornberger et al. [27] Clin J Pain 2008 NA USD 26,005 (nonrechargeable)
USD 35,109 (rechargeable)
5. Babu et al. [28] Neuromodulation 2013 4536 USD 30,200 (percutaneous)
4536 USD 29,963 (paddle electrodes)
6. Annemans et al. [29] J LTE Med Implants 2014 Model UK£ 15,056 (HF SCS)
Table 1. 




1. Repositioning of electrode €360 $2700
2. Replacement €1530 $5450
3. Reimplantation following infection €6192 $19,600
Table 3. 
Costs for lead revision/repositioning in TSCS.
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to enhance the quality of neuromodulation in the field of functional neurosurgery 
and pain management therapies. Wireless neuromodulation, so far applied as SCS, 
DRG, and PNS, has provided efficient pain relief in cases of FBSS, neuralgic pain, 
CRPS, and facial pain syndromes. The results observed in small case series or case 
illustrations are comparable to traditional SCS methods and devoid of many of 
the complications of TSCS, primarily related to IPG/battery accessories. Further 
wireless neuromodulation experience may demonstrate improved quality of life 
associated with significant reduction in cost as well as reduction in complications, 
with improved cosmetic and functional results.
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